Delivery of a Chlamydial Adhesin N-PmpC Subunit Vaccine to the Ocular Mucosa Using Particulate Carriers.

Trachoma, caused by the intracellular bacterium Chlamydia trachomatis (Ct), remains the world's leading preventable infectious cause of blindness. Recent attempts to develop effective vaccines rely on modified chlamydial antigen delivery platforms. As the mechanisms engaged in the pathology of...

Full description

Bibliographic Details
Main Authors: Aleksandra Inic-Kanada, Marijana Stojanovic, Simone Schlacher, Elisabeth Stein, Sandra Belij-Rammerstorfer, Emilija Marinkovic, Ivana Lukic, Jacqueline Montanaro, Nadine Schuerer, Nora Bintner, Vesna Kovacevic-Jovanovic, Ognjen Krnjaja, Ulrike Beate Mayr, Werner Lubitz, Talin Barisani-Asenbauer
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4684359?pdf=render
id doaj-dc5ebd2f6146475db14dc5707e7a4970
record_format Article
spelling doaj-dc5ebd2f6146475db14dc5707e7a49702020-11-25T02:25:02ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011012e014438010.1371/journal.pone.0144380Delivery of a Chlamydial Adhesin N-PmpC Subunit Vaccine to the Ocular Mucosa Using Particulate Carriers.Aleksandra Inic-KanadaMarijana StojanovicSimone SchlacherElisabeth SteinSandra Belij-RammerstorferEmilija MarinkovicIvana LukicJacqueline MontanaroNadine SchuererNora BintnerVesna Kovacevic-JovanovicOgnjen KrnjajaUlrike Beate MayrWerner LubitzTalin Barisani-AsenbauerTrachoma, caused by the intracellular bacterium Chlamydia trachomatis (Ct), remains the world's leading preventable infectious cause of blindness. Recent attempts to develop effective vaccines rely on modified chlamydial antigen delivery platforms. As the mechanisms engaged in the pathology of the disease are not fully understood, designing a subunit vaccine specific to chlamydial antigens could improve safety for human use. We propose the delivery of chlamydia-specific antigens to the ocular mucosa using particulate carriers, bacterial ghosts (BGs). We therefore characterized humoral and cellular immune responses after conjunctival and subcutaneous immunization with a N-terminal portion (amino acid 1-893) of the chlamydial polymorphic membrane protein C (PmpC) of Ct serovar B, expressed in probiotic Escherichia coli Nissle 1917 bacterial ghosts (EcN BGs) in BALB/c mice. Three immunizations were performed at two-week intervals, and the immune responses were evaluated two weeks after the final immunization in mice. In a guinea pig model of ocular infection animals were immunized in the same manner as the mice, and protection against challenge was assessed two weeks after the last immunization. N-PmpC was successfully expressed within BGs and delivery to the ocular mucosa was well tolerated without signs of inflammation. N-PmpC-specific mucosal IgA levels in tears yielded significantly increased levels in the group immunized via the conjunctiva compared with the subcutaneously immunized mice. Immunization with N-PmpC EcN BGs via both immunization routes prompted the establishment of an N-PmpC-specific IFNγ immune response. Immunization via the conjunctiva resulted in a decrease in intensity of the transitional inflammatory reaction in conjunctiva of challenged guinea pigs compared with subcutaneously and non-immunized animals. The delivery of the chlamydial subunit vaccine to the ocular mucosa using a particulate carrier, such as BGs, induced both humoral and cellular immune responses. Further investigations are needed to improve the immunization scheme and dosage.http://europepmc.org/articles/PMC4684359?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Aleksandra Inic-Kanada
Marijana Stojanovic
Simone Schlacher
Elisabeth Stein
Sandra Belij-Rammerstorfer
Emilija Marinkovic
Ivana Lukic
Jacqueline Montanaro
Nadine Schuerer
Nora Bintner
Vesna Kovacevic-Jovanovic
Ognjen Krnjaja
Ulrike Beate Mayr
Werner Lubitz
Talin Barisani-Asenbauer
spellingShingle Aleksandra Inic-Kanada
Marijana Stojanovic
Simone Schlacher
Elisabeth Stein
Sandra Belij-Rammerstorfer
Emilija Marinkovic
Ivana Lukic
Jacqueline Montanaro
Nadine Schuerer
Nora Bintner
Vesna Kovacevic-Jovanovic
Ognjen Krnjaja
Ulrike Beate Mayr
Werner Lubitz
Talin Barisani-Asenbauer
Delivery of a Chlamydial Adhesin N-PmpC Subunit Vaccine to the Ocular Mucosa Using Particulate Carriers.
PLoS ONE
author_facet Aleksandra Inic-Kanada
Marijana Stojanovic
Simone Schlacher
Elisabeth Stein
Sandra Belij-Rammerstorfer
Emilija Marinkovic
Ivana Lukic
Jacqueline Montanaro
Nadine Schuerer
Nora Bintner
Vesna Kovacevic-Jovanovic
Ognjen Krnjaja
Ulrike Beate Mayr
Werner Lubitz
Talin Barisani-Asenbauer
author_sort Aleksandra Inic-Kanada
title Delivery of a Chlamydial Adhesin N-PmpC Subunit Vaccine to the Ocular Mucosa Using Particulate Carriers.
title_short Delivery of a Chlamydial Adhesin N-PmpC Subunit Vaccine to the Ocular Mucosa Using Particulate Carriers.
title_full Delivery of a Chlamydial Adhesin N-PmpC Subunit Vaccine to the Ocular Mucosa Using Particulate Carriers.
title_fullStr Delivery of a Chlamydial Adhesin N-PmpC Subunit Vaccine to the Ocular Mucosa Using Particulate Carriers.
title_full_unstemmed Delivery of a Chlamydial Adhesin N-PmpC Subunit Vaccine to the Ocular Mucosa Using Particulate Carriers.
title_sort delivery of a chlamydial adhesin n-pmpc subunit vaccine to the ocular mucosa using particulate carriers.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description Trachoma, caused by the intracellular bacterium Chlamydia trachomatis (Ct), remains the world's leading preventable infectious cause of blindness. Recent attempts to develop effective vaccines rely on modified chlamydial antigen delivery platforms. As the mechanisms engaged in the pathology of the disease are not fully understood, designing a subunit vaccine specific to chlamydial antigens could improve safety for human use. We propose the delivery of chlamydia-specific antigens to the ocular mucosa using particulate carriers, bacterial ghosts (BGs). We therefore characterized humoral and cellular immune responses after conjunctival and subcutaneous immunization with a N-terminal portion (amino acid 1-893) of the chlamydial polymorphic membrane protein C (PmpC) of Ct serovar B, expressed in probiotic Escherichia coli Nissle 1917 bacterial ghosts (EcN BGs) in BALB/c mice. Three immunizations were performed at two-week intervals, and the immune responses were evaluated two weeks after the final immunization in mice. In a guinea pig model of ocular infection animals were immunized in the same manner as the mice, and protection against challenge was assessed two weeks after the last immunization. N-PmpC was successfully expressed within BGs and delivery to the ocular mucosa was well tolerated without signs of inflammation. N-PmpC-specific mucosal IgA levels in tears yielded significantly increased levels in the group immunized via the conjunctiva compared with the subcutaneously immunized mice. Immunization with N-PmpC EcN BGs via both immunization routes prompted the establishment of an N-PmpC-specific IFNγ immune response. Immunization via the conjunctiva resulted in a decrease in intensity of the transitional inflammatory reaction in conjunctiva of challenged guinea pigs compared with subcutaneously and non-immunized animals. The delivery of the chlamydial subunit vaccine to the ocular mucosa using a particulate carrier, such as BGs, induced both humoral and cellular immune responses. Further investigations are needed to improve the immunization scheme and dosage.
url http://europepmc.org/articles/PMC4684359?pdf=render
work_keys_str_mv AT aleksandrainickanada deliveryofachlamydialadhesinnpmpcsubunitvaccinetotheocularmucosausingparticulatecarriers
AT marijanastojanovic deliveryofachlamydialadhesinnpmpcsubunitvaccinetotheocularmucosausingparticulatecarriers
AT simoneschlacher deliveryofachlamydialadhesinnpmpcsubunitvaccinetotheocularmucosausingparticulatecarriers
AT elisabethstein deliveryofachlamydialadhesinnpmpcsubunitvaccinetotheocularmucosausingparticulatecarriers
AT sandrabelijrammerstorfer deliveryofachlamydialadhesinnpmpcsubunitvaccinetotheocularmucosausingparticulatecarriers
AT emilijamarinkovic deliveryofachlamydialadhesinnpmpcsubunitvaccinetotheocularmucosausingparticulatecarriers
AT ivanalukic deliveryofachlamydialadhesinnpmpcsubunitvaccinetotheocularmucosausingparticulatecarriers
AT jacquelinemontanaro deliveryofachlamydialadhesinnpmpcsubunitvaccinetotheocularmucosausingparticulatecarriers
AT nadineschuerer deliveryofachlamydialadhesinnpmpcsubunitvaccinetotheocularmucosausingparticulatecarriers
AT norabintner deliveryofachlamydialadhesinnpmpcsubunitvaccinetotheocularmucosausingparticulatecarriers
AT vesnakovacevicjovanovic deliveryofachlamydialadhesinnpmpcsubunitvaccinetotheocularmucosausingparticulatecarriers
AT ognjenkrnjaja deliveryofachlamydialadhesinnpmpcsubunitvaccinetotheocularmucosausingparticulatecarriers
AT ulrikebeatemayr deliveryofachlamydialadhesinnpmpcsubunitvaccinetotheocularmucosausingparticulatecarriers
AT wernerlubitz deliveryofachlamydialadhesinnpmpcsubunitvaccinetotheocularmucosausingparticulatecarriers
AT talinbarisaniasenbauer deliveryofachlamydialadhesinnpmpcsubunitvaccinetotheocularmucosausingparticulatecarriers
_version_ 1724853132137070592